Research Article
Aldosterone Blockade in Acute Myocardial Infarction: A Systematic Review and Meta-Analysis
Table 2
Baseline characteristics of patients included in the meta-analysis.
| | Author (year) | Comparison Drug (mg/d) | Patients Number | Cr (mg/dl)
K (mmol/l) | LVEF (%)
Killip class | Age
Male (female) | | MRA/non-MRA |
| | Rodríguez [17] (1997) | SP (75) vs. P | AMI/47 | <2.0
NA | NR
NR | 58.8 (10.8)/58.6 (9.0)b
18 (5)/22 (2) | | Modena [18] (2001) | vs. | STEMI, 6 ha/46 | ≤2.5
NA | >40
I-III | 59.0 (10.0)/62.0 (13.0)
17 (7)/17 (5) | | Pitt [11] (2003) | | AMI, LVSD, (3-14 d)/6632 | ≤2.5
≤5.0 | ≤40
NR | 64.0 (11.0)/64.0 (12.0)
2380 (939)/2334 (979) | | Hayashi [19] (2003) | vs. ACEI | STEMI, SR, 24 h/150 | ≤2.0
≤5.0 | >40
I-II | 64.4 (1.4)/62.9 (1.4)
49 (16)/51 (18) | | Di Pasquale [20] (2001) | | STEMI, 4 h/187 | ≤2.0
≤5.0 | >40
I-II | 63.6 (15.0)/62.8 (16.0)
62 (32)/61 (32) | | Di Pasquale [21] (2005) | | STEMI, 4 h/687 | ≤2.0
≤5.0 | >40
I-II | 62.6 (6.0)/62.8 (5.0)
243 (98)/244 (102) | | Uzunhasan [22] (2009) | | STEMI, SR, 6-12 h/82 | ≤2.5
≤5.0 | >40
I-II | 52.0 (10.0)/52.0 (10.0)
32 (9)/29 (11) | | Kayrak [23] (2010) | | STEMI, SR, 12 h/142 | ≤2.0
≤5.0 | ≥40
I-II | 55.3 (10.0)/57.2 (11.1)
10 (45)/14 (41) | | Weir [24] (2011) | | AMI, LVSD (1-14 d)/100 | ≤2.5
≤5.0 | <40
I | 61.0 (12.0)/56.8 (12.0)
37 (13)/40 (10) | | Kampourides [25] (2012) | vs. ST | STEMI, 24 h/327 | ≤2.5
≤5.0 | ≥40
I | ND | | Wu [26] (2013) | ST + SP (20) vs.ST | STEMI, 24 h/616 | ≤2.5
≤5.0 | >40
I-III | 59.8 (11.7)/59.9 (10.3)
193 (69)/192 (74) | | Vatankulu [27] (2013) | (12.5-5) vs. ST | STEMI, SR/110 | ≤2.0
<5.5 | ≥40
I-II | 56.0 (10.1)/57.0 (11.0)
89 (15)/45 (11) | | Montalescot [28] (2014) | (50) vs. | STEMI, 24 h/1012 | <2.5
NA | >40
NR | 58.5 (10.8)/57.8 (11.0)
420 (86)/403 (103) | | Beygui [12] (2016) | vs. ST | AMI, 72 h/1603 | <2.5
<5.5 | >40
I-IV | 58.0 (13.0)/58.0 (13.0)
673 (129)/658 (143) | | Bulluck [13] (2019) | SP (50) vs. P | STEMI, 12 h/70 | NA
<5.0 | >40
I | 62.0 (10.0)/60.0 (13.0)
33 (5)/27 (5) |
|
|
aTime from disease onset to trial entry; bmean (standard deviation). EP: eplerenone; SP: spironolactone; CAN: canrenoate; CAP: captopril; ST: standard therapy; ACEI: angiotensin converting enzyme inhibitors; P: placebo; LVEF: left ventricular ejection fraction; LVSD: left ventricular systolic dysfunction; AMI: acute myocardial infarction; STEMI: ST-segment elevation myocardial infarction; MRA: mineralocorticoid receptor antagonists; SR: successful reperfusion; ND: not defined; NR: not restricted; NA: not available; Cr: creatinine; K: kalium.
|
